Park, KeunchilKeunchilParkÖzgüroğlu, MustafaMustafaÖzgüroğluVansteenkiste, JohanJohanVansteenkisteSpigel, DavidDavidSpigelCHIH-HSIN YANGIshii, HidenobuHidenobuIshiiGarassino, MarinaMarinaGarassinode Marinis, FilippoFilippode MarinisSzczesna, AleksandraAleksandraSzczesnaPolychronis, AndreasAndreasPolychronisUslu, RuchanRuchanUsluKrzakowski, MaciejMaciejKrzakowskiLee, Jong-SeokJong-SeokLeeCalabrò, LuanaLuanaCalabròArén Frontera, OsvaldoOsvaldoArén FronteraXiong, HuilingHuilingXiongBajars, MarcisMarcisBajarsRuisi, MaryMaryRuisiBarlesi, FabriceFabriceBarlesi2022-01-052022-01-0520211556-0864https://scholars.lib.ntu.edu.tw/handle/123456789/590974In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.enAvelumab; Non–small cell lung cancer; PD-L1; Phase 3; Second-line[SDGs]SDG3avelumab; docetaxel; monoclonal antibody; platinum; programmed death 1 ligand 1; clinical trial; controlled study; follow up; human; lung; lung tumor; phase 3 clinical trial; randomized controlled trial; tumor recurrence; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Docetaxel; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Platinumjournal article10.1016/j.jtho.2021.03.009338452112-s2.0-85105584972WOS:000677967100019https://api.elsevier.com/content/abstract/scopus_id/85105584972